Neuropathix, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NPTX research report →
Price Chart
About the company
Neuropathix, Inc. is a biopharmaceutical firm dedicated to identifying, advancing, and bringing to market innovative treatments derived from its exclusive platform of synthetic cannabinoid derivatives. The company's efforts are concentrated on the research and preclinical development of chemical compounds like KLS-13019, KLS-13023, and KLS-13022, alongside associated molecules and synthetic cannabidiol-based therapies.
- CEO
- Dean Petkanas
- IPO
- 2019
- Employees
- 6
- HQ
- Doylestown, PA, US
Get TickerSpark's AI analysis on NPTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $28.14K
- P/E
- -0.01
- PEG
- -0.00
- P/S
- 0.15
- P/B
- -0.01
- EV/EBITDA
- -0.66
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1602.73%
- Net Margin
- -2175.95%
- ROE
- 111.19%
- ROIC
- 217.12%
Latest fiscal year · YoY change
- Revenue
- $183.48K+0.0%
- Gross Profit
- $183.48K+0.0%
- Op Income
- $-2,940,636
- Net Income
- $-3,992,375+28.3%
- EPS
- $-0.05+38.9%
- OCF Growth
- +5.8%
- FCF Growth
- +5.1%
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- 1.65
- RSI (14)
- 47
- Avg Volume
- 13.60K
No earnings-call transcripts are available for NPTX yet.
- Free Float
- 39.0%
- Shares Outstanding
- 93.81M
- Float Shares
- 36.59M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 6, 22 | PETKANAS DEAN | sell | 10,000 |
| Jun 7, 22 | PETKANAS DEAN | sell | 50,000 |
| Jun 8, 22 | PETKANAS DEAN | sell | 21,836 |
| Jun 9, 22 | PETKANAS DEAN | sell | 238,164 |
| Jun 13, 22 | PETKANAS DEAN | other | 300,000 |
| Jun 13, 22 | PETKANAS DEAN | other | 100,000 |
| May 26, 22 | PETKANAS DEAN | sell | 100,000 |
| May 27, 22 | PETKANAS DEAN | sell | 50,000 |
| May 31, 22 | PETKANAS DEAN | sell | 10,000 |
| May 31, 22 | PETKANAS DEAN | sell | 20,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NPTX coverage
Recent articles, reports, and earnings notes.
No research on NPTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NPTX report →Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)
accesswire.com · Sep 28
Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company's Over-The-Counter Cosmeceutical Assets
accesswire.com · Aug 24
Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders
accesswire.com · Jul 20
Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead
globenewswire.com · Jan 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.